Table 3.

Efficacy of SHR-1210 and apatinib combination treatment in patients with HCC or GC/EGJC

HCC (n = 18)GC/EGJC (n = 25)Overall (n = 43)
Confirmed objective responsea8 (44.4%)4 (16.0%)12 (27.9%)
 Complete response000
 Partial response8 (44.4%)5 (20.0%)12 (27.9%)
 Stable disease ≥6 weeks7(38.9%)13 (52.0%)21 (48.8%)
 Progressive disease1 (5.6%)5 (20.0%)6 (14.0%)
 Not evaluable2 (11.1%)2 (8.0%)4 (9.3%)
ORR in evaluable patients50.0% (24.7%, 75.4%)17.4% (5.0%, 38.9%)30.8% (17.0%, 47.6%)
DCR in evaluable patients93.8% (69.8%, 99.8%)78.3% (56.3%, 92.5%)84.6% (69.5%, 94.1%)
Median time to response3.4 (1.4∼9.7)2.8 (1.4∼6.0)3.45 (1.4∼9.7)
Duration of response
 KM medianNR4.7NR
 Ongoing, n/N (%)7/8 (87.5%)1/4 (25%)8/12 (66.7%)
PFS
 KM median5.8 (2.6,NR)2.9 (2.5, 4.2)4.2 (2.8, 5.8)
 6 months45.4% (20.9%, 67.1%)25.3% (9.7%, 44.4%)33.9% (19.5%, 48.9%)
 9 months37.8% (15.0%, 60.7%)12.6% (2.4%, 31.7%)23.7% (11.2%, 38.8%)
 APTN-250 mg/day7.2 (4.1, NR)2.9 (2.5, 6.1)4.4 (2.9, 6.6)
OS
 KM medianNR (4.0, NR)11.4 (8.6, NR)12.6 (8.6, NR)
 APTN-250 mg/dayNR (8.2, NR)11.4(8.9, NR)NR (9.9, NR)
  • NOTE: Data are n (%); % (95% CI) or months (95% CI).

  • aResponse was assessed in all enrolled patients.